Search - tctmd.com

Displaying 481 - 500 of 603

Sort: Relevancy | Date

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

Most PAD Patients ‘Dramatically Undertreated’ With Preventive Meds, Lifestyle Counseling

L.A. McKeown

May 01, 2017

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

News Daily News

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Alison Palkhivala

April 11, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

Presentation ACC 2017

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Presenter: Robert Giugliano

March 19, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Presentation ACC 2017

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Presenter: Marc Sabatine

March 17, 2017

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News ISC 2017

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Todd Neale

February 24, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Daily News

Even With Early Invasive Strategy in NSTE ACS, Women Face Poorer Outcomes Than Men

Caitlin E. Cox

January 24, 2017

Advertisement

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Most PAD Patients ‘Dramatically Undertreated’ With Preventive Meds, Lifestyle Counseling

Who Should Get a Statin? Guidelines Don’t Match Up

One in Five Acute MI Patients Drop Statins Within 2 Years

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Even With Early Invasive Strategy in NSTE ACS, Women Face Poorer Outcomes Than Men

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content